Chronic Obstructive Pulmonary Disease (COPD)

Definition

• Robbins Basic Pathology: COPD is characterized by functional outflow obstruction due to loss of elastic tissue in alveolar walls; associated with reduced FEV1 and normal or near-normal FVC.

Epidemiology

• Third most common cause of death in the United States
• Accounts for more than $40 billion per year in direct and indirect healthcare costs
• Traditionally attributed to 15-30% of habitual smokers, though modern CT imaging reveals important progressive changes even in smokers with normal spirometry

Components

1. Emphysema

• Enlargement of air spaces distal to the terminal bronchioles caused by destruction of elastic support structures by proteases (especially from neutrophils)
• Centriacinar (centrilobular): most common; smoking-related; upper lobe predominance
• Panacinar: seen in alpha-1 antitrypsin (AAT) deficiency; lower lobe predominance
• Clinical features: barrel chest, increased chest volume, dyspnea, relatively preserved O2 at rest ("pink puffer")

2. Chronic Bronchitis

• Defined as persistent productive cough for at least 3 consecutive months in at least 2 consecutive years (clinical definition)
• Caused by mucus overproduction in proximal airways from surface epithelial mucous metaplasia and submucosal gland expansion, combined with ciliary dysfunction
• Histology: enlargement of mucus-secreting glands, goblet cell metaplasia, small airway inflammation, bronchiolar wall fibrosis
• Clinical features: productive cough, hypoxemia, hypercapnia, cyanosis ("blue bloater")

Pathogenesis

Pulmonary Function Tests

Pathophysiology of Gas Exchange Abnormalities

• V/Q mismatch is the primary mechanism of hypoxemia - blood perfuses poorly ventilated alveoli, reducing arterial PO2
• Dynamic hyperinflation: reduced elastic recoil + air trapping raises TLC and FRC; tidal breathing shifts to upper flow-volume curve
• Hypercapnia typically doesn't develop until FEV1 falls to ~20-25% of predicted
• Causes: increased physiologic dead space, V/Q mismatch, and mechanical disadvantage of a flattened, over-stretched diaphragm
• Diaphragmatic changes in COPD include: reduced force per cross-sectional area, reduced myosin heavy chain content, decreased Ca2+ sensitivity, and slower cross-bridge cycling

Clinical Features

• Progressive exertional dyspnea (most common presenting symptom)
• Chronic productive cough (bronchitic component)
• Barrel chest, prolonged expiration, accessory muscle use, pursed-lip breathing
• Wheezing, reduced breath sounds
• Digital clubbing (not typical - if present, suspect lung cancer)
• Cor pulmonale (right heart failure) in advanced disease from chronic hypoxic pulmonary vasoconstriction

Pharmacological Treatment (GOLD-guided)

Bronchodilators (Mainstay)

Inhaled Corticosteroids (ICS)

• Less central in COPD than in asthma; associated with increased risk of bacterial pneumonia
• Recommended only for: severe airflow obstruction (FEV1 < 50%), history of frequent exacerbations, and/or blood eosinophils ≥300 cells/μL
• High eosinophil count predicts ICS response (eosinophil-guided therapy)

Other Agents

• Roflumilast (PDE4 inhibitor): reduces exacerbation frequency in severe COPD with chronic bronchitis phenotype; approved for add-on therapy
• Theophylline: older agent; a recent large placebo-controlled RCT showed no benefit on exacerbation frequency at low doses; not routinely recommended
• N-acetylcysteine (NAC): mucolytic; modest evidence for reducing exacerbations in selected patients
• Azithromycin: chronic macrolide therapy reduces exacerbation frequency in former smokers

Oxygen Therapy

• Long-term O2 therapy (LTOT) if resting PaO2 ≤ 55 mmHg or SaO2 ≤ 88% - the only pharmacological intervention shown to improve survival in hypoxemic COPD
• Goal: maintain SaO2 ≥ 90%

COPD Exacerbations

• Defined as: acute worsening of respiratory symptoms beyond normal day-to-day variation requiring additional therapy
• Triggers: viral infections (most common, ~50-70%), bacterial infection (H. influenzae, S. pneumoniae, M. catarrhalis), air pollution, unknown causes
• Management:
  • Intensify bronchodilators (SABA ± SAMA)
  • Systemic corticosteroids (prednisolone 40 mg/day x 5 days)
  • Antibiotics (beta-lactams, macrolides, fluoroquinolones) - given routinely given high rate of bacterial involvement
  • Controlled O2 (target SaO2 88-92% to avoid hypercapnic drive suppression)
  • NIV (non-invasive ventilation) for hypercapnic respiratory failure (pH < 7.35, PaCO2 > 45)
  • Mortality is higher than asthma exacerbations due to older patient age and cardiovascular comorbidities

Non-Pharmacological Management

• Smoking cessation: single most important intervention; slows FEV1 decline
• Pulmonary rehabilitation: improves dyspnea, exercise tolerance, and quality of life
• Vaccination: influenza (annual), pneumococcal, COVID-19
• Nutritional support: weight loss is a poor prognostic marker
• Surgical options (severe disease): lung volume reduction surgery (LVRS), bullectomy, lung transplantation

COPD vs Asthma - Key Differences

Complications

• Cor pulmonale (right heart failure)
• Secondary polycythemia (chronic hypoxia → EPO stimulation)
• Spontaneous pneumothorax (ruptured bullae)
• Respiratory failure (hypercapnic or hypoxemic)
• Lung cancer (independent risk from smoking)
• Sleep-disordered breathing / overlap syndrome

Recent Evidence (2024-2026)

Tapetum - Functions

1. Tapetum Lucidum (Eye)

Functions:

Trade-off:

Mechanism:

Neuroscience: Exploring the Brain, 5th Ed.: "Many nocturnal animals, such as cats and raccoons, have a reflective layer beneath the photoreceptors, called the tapetum lucidum, which bounces light back at the photoreceptors if it passes through the retina. The animal is thus more sensitive to low light levels at the expense of reduced acuity."

2. Tapetum of the Corpus Callosum (Brain)

Location:

Functions:

Localization in Clinical Neurology, 8th Ed.: "Area MT projects contralaterally through the tapetum, major forceps, and splenium of the corpus callosum to areas MT and MST of the contralateral hemisphere."

Summary Table